Firefly Neuroscience is trading 5.91% down now at $1.05 as broader markets weaken amid Middle East tensions, higher oil prices, rising yields, and renewed rate concerns.
- No new company-specific announcement or confirmed catalyst was identified for September 1, 2026.
- The healthcare sector is stronger, so sector strength does not explain the move.
- The latest notable company update remains the August 5 brain-scan volume report.